John Charles Thomas Sells 1,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) EVP John Charles Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Charles Thomas also recently made the following trade(s):

• On Tuesday, May 26th, John Charles Thomas sold 642 shares of Krystal Biotech stock. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $372.25 on Friday. The stock has a market capitalization of $10.97 billion, a P/E ratio of 49.77 and a beta of 0.53. Krystal Biotech, Inc. has a 1 year low of $130.50 and a 1 year high of $376.28. The business’s fifty day moving average is $304.72 and its two-hundred day moving average is $276.69.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, research analysts forecast that Krystal Biotech, Inc. will post 7.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on KRYS shares. Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research report on Tuesday, June 16th. Citigroup boosted their price objective on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Wolfe Research began coverage on shares of Krystal Biotech in a report on Friday, March 27th. They issued a “peer perform” rating for the company. Finally, TD Cowen lifted their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $340.56.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada lifted its holdings in shares of Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after buying an additional 964 shares during the last quarter. AQR Capital Management LLC raised its position in Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after acquiring an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after acquiring an additional 688 shares in the last quarter. Empowered Funds LLC bought a new position in Krystal Biotech during the first quarter valued at approximately $218,000. Finally, Cetera Investment Advisers lifted its stake in Krystal Biotech by 107.9% in the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after acquiring an additional 2,255 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.